Interim updated planning guidance on allocating and targeting pandemic influenza vaccine during an influenza pandemic

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  These guidelines replace the 2008 Guidance on Allocating and Targeting Pandemic Influenza Vaccine. This document was developed to update and provide interim guidance for planning purposes and to provide the rationale for a national vaccination program during a pandemic that also allows or local adjustment where appropriate. National guidance for targeting pandemic influenza vaccination planning is provided with the under- standing that the numbers of people within each group are estimates for planning purposes and actual recommendations may change for a future pandemic and as the pandemic progresses.
  
  The 2008 Guidance was developed based on key scientific information and extensive input from the public and stakeholders, including businesses and community organizations, who provided key perspectives on public values and priorities about which subgroups would require the earli- est vaccine protection in the event of an influenza pandemic. The principles about the core objectives and guiding principles established previously with stakeholders are preserved in this document.
  
  Several new elements have been incorporated into the 2018 guidelines. First, the guidance uses updated pandemic severity categories based on
  
  the current CDC Pandemic Severity Assessment Framework1. Second, the updated guidance incorporates lessons learned from the 2009 H1N1 pandemic response, such as the unpredictability of pandemic severity and timing, variability of the impact of pandemic severity on critical infrastructure functions, challenges with vaccine supply overall and variability among manufacturers, and the need for flexibility at the state, tribal, and local levels to best manage vaccine supplies to meet local needs. Third, this document includes the consideration that two doses of vaccine and co-administration of adjuvant may be required to produce protective immunity in some scenarios. Fourth, pharmacists and pharmacy technicians are included in Tier 1a, since pharmacists (and pharmacy technicians) will be crucial to antiviral dispensing and many pharmacists will be pandem- ic vaccine immunizers. Finally, the estimated numbers of population groups are based on 2015 U.S. Census population estimates.
  
  2018-Influenza-Guidance.pdf
  
  
• Content Notes:
  Introduction -- Guidance Development and Revision -- Vaccination of Tier 1 at All Pandemic Severities -- Implementation of this Guidance during a Future Pandemic -- Vaccination Tier 2 through 5 by Pandemic Severity -- Next Steps for the U.S. Government, States, and Communities -- References -- Appendix A. Description and Rationale for Population Groups Targeted for Pandemic Vaccination.
• Subjects:
  Disaster Planning Influenza, Human Influenza Vaccines Pandemics
• Document Type:
  Pamphlet (or booklet)
• Genre:
  Guidance
• Pages in Document:
  25 numbered pages
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:9279932bfb951960d80af0c70f7609302398b4521d998e46f474931e3c683074
• Download URL:
  https://stacks.cdc.gov/view/cdc/60431/cdc_60431_DS1.pdf
• File Type:
  [PDF - 2.15 MB ]